WE HAVE 2 NEW TYSABRI EDITORS STARTING 4/15/10! THEY WIL BE POSTING TYSABRI NEWS EVERY DAY!
Showing posts with label 500 BEST PML STORIES & STUDIES. Show all posts
Showing posts with label 500 BEST PML STORIES & STUDIES. Show all posts
Wednesday, April 27
MS drug influences John Cunningham virus antibody levels
Image Source: UNI-MUENSTER
The multiple sclerosis treatment Tysabri (natalizumab) may be associated with increased levels of John Cunningham virus antibodies, indicating increased risk for fatal brain disease caused by the infection, according to recent data.
Wednesday, April 20
Monitoring the John Cunningham virus throughout Tysabri (natalizumab) treatment in MS patients: STUDY
Thursday, April 7
Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy (PML): Risks and Detection: VIDEO
Fred Lublin, MD, explains that prior to the use of Tysabri (natalizumab), progressive multifocal leukoencephalopathy (PML) had never been observed in patients with multiple sclerosis (MS). Providing accurate figures about the risk of PML to patients who may be or are being treated with natalizumab iscritically important in makingthe best treatment choices. PML is not as severe and lethal in the setting of MS as in other diseases, such as HIV. Still, he adds,PML often leaves individuals left with some kind of disability, and the mortality rate in MS is about 20%.
Thursday, July 2
Researchers Suggest Short Transition Period Between Tysabri (Natalizumab) and Gilenya (Fingolimod) Therapies to Control RRMS Disease Activity
An international team led by researchers at the University Hospital Basel in Switzerland revealed that a short period of 8 to 12 weeks is the optimal timing to be considered when patients with relapsing-remitting multiple sclerosis (RRMS) are switched from natalizumab to fingolimod therapy. The study was recently published in the journal Neurology and is entitled “Switching from natalizumab to fingolimod, A randomized, placebo-controlled study in RRMS.”
Saturday, February 7
Saturday, January 10
Tecfidera-Related Progressive Multifocal Leukoencephalopathy (PML) Reported
Friday, May 16
S*** NHS England green-lights switch from Tysabri to Gilenya in MSers at high-risk of PML
NHS England green-lights switch from natalizumab to fingolimod in MSers at high-risk of PML#MSBlog #MSResearch #ClinicSpeak
Interferon-beta, GA or steroids not good enough to prevent rebound activity #MSBlog #MSResearch #ClinicSpeak
"The
study below confirms what we already know; stopping natalizumab leads
to rebound in MS disease activity. Switching to a DMT on a lower-tier of
efficacy, i.e. interferon-beta or glatiramer acetate, or taking
steroids does not prevent this rebound. In comparison, a higher-efficacy
drug such as fingolimod appears to prevent this rebound provided it is started within 4 weeks after the last natalizumab infusion."
"Most
MSers stopping natalizumab are doing it because they are at high-risk
of developing PML. The major safety concern we have is so called
carry-over PML; i.e. PML that presents in the first few months after
starting fingolimod. I am aware of two cases of carry-over PML on
fingolimod. Carry-over PML is a problem in that we rely on the immune
response to clear you of PML; it takes about 6-8 weeks for fingolimod to
wash-out of your system and during this time PML can cause devastating
damage. Our practice, to prevent carry-over PML and rebound disease
activity, is to do a MRI and lumbar puncture shortly after the last
natalizumab infusion. If the spinal fluid analysis shows no JC virus DNA
and the MRI shows no evidence of asymptomatic PML we start fingolimod
within 4 weeks of the last natalizumab infusion. So far this practice
seems to be working; touch wood we have had no cases of carry-over
PML."
"In
clinic last week someone asked me about switching from natalizumab to
alemtuzumab? Alemtuzumab is an induction agent and hence you can't
reverse its action. If you developed carry-over PML after switching from
natalizumab to alemtuzumab the chances are you will die from the PML as
your immune system will not be able to respond quickly enough to clear
the virus. Post alemtuzumab it takes over 3 months for your immune
system to recover. For this reason I am telling my patients that it will
be much safer for them to switch to a maintenance agent, for example
fingolimod, for several months or years, before switching to alemtuzumab
post-natalizumab. The latter advice is not evidence-based and is
unlikely to become evidence-based in the future; this advice is based in
scientific principles on how the different DMTs affect your immune
system."
"For
UK MSers who read this blog we have finally been given the green-light
by NHS England to switch MSers at high-risk of PML on natalizumab to fingolimod, who have never been treated with interferon-beta or GA in the past.
Epub: Fox et al. MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study.Neurology. 2014 Mar.
OBJECTIVE: RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab.
CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for MSers with MS taking natalizumab who are relapse-free for 1 year, stopping natalizumab increases the risk of MS relapse or MRI disease activity as compared with continuing natalizumab.
OBJECTIVE: RESTORE was a randomized, partially placebo-controlled exploratory study evaluating multiple sclerosis (MS) disease activity during a 24-week interruption of natalizumab.
METHODS: Eligible
MSers were relapse-free through the prior year on natalizumab and had
no gadolinium-enhancing lesions on screening brain MRI. MSers were
randomized 1:1:2 to continue natalizumab, to switch to placebo, or to
receive alternative immunomodulatory therapy (other therapies: IM
interferon β-1a [IM IFN-β-1a], glatiramer acetate [GA], or
methylprednisolone [MP]). During the 24-week randomized treatment
period, MSers underwent clinical and MRI assessments every 4 weeks.
CONCLUSIONS: MRI and clinical disease activity recurred in some patients during natalizumab interruption, despite use of other therapies.
CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for MSers with MS taking natalizumab who are relapse-free for 1 year, stopping natalizumab increases the risk of MS relapse or MRI disease activity as compared with continuing natalizumab.
http://multiple-sclerosis-research.blogspot.com/2014/04/clinic-speak-what-happens-when-you-stop.html?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+blogspot%2FWvYVL+%28Multiple+Sclerosis+Research%29
STUDY: Tysabri (Natalizumab) to Gilenya (fingolimod) washout in patients at risk of PML
Upon
withdrawing natalizumab, resumption of disease activity was soon
observed, beginning 3–4 months after the last dose of natalizumab
BREAKING NEWS ON PML: FDA probes brain infection in patient with MS drug PML
US
FDA raised an alert in Europe after emergence of a case of progressive
multifocal leukoencephalopathy (PML), following the administration of
Novartis multiple sclerosis drug Gilenya
FDA investigates multifocal leukoencephalopathy (PML) in patient on Novartis multiple sclerosis drug Gilenya
HERE'S A NEW EDITORIAL ABOUT TYSABRI AND THE PML PROBLEM FOR MSers NEEDING TO QUIT TYSABRI
Tysabri/Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy
Jayce Parente, Columnist, MSnewsChannel.com
![]() |
Jayce Parente, Columnist, MSnewsChannel.com |
Am I ok?
Are these MS symptoms?
Are they the potentially lethal PML symptoms?
I've been told to be "mindful" of PML symptoms yet PML symptoms and MS relapse symptoms are identical.
I know you're gonna say call my "Care Team" but what good is that when they are going to give me a script for a blood test in which it will take me a few days until I can have blood drawn only to wait a few days to get the results when I'm "supposed" to act QUICKLY?
So let me get this straight? I've taken a drug for 2 years that has been linked to causing progressive multifocal leukoencephalopathy (PML). I just stopped taking this drug and am currently detoxing from it.
I also have started to generate more intense symptoms SINCE stopping this drug. Are these MS symptoms?
Are they the potentially lethal PML symptoms?
I've been told to be "mindful" of PML symptoms yet PML symptoms and MS relapse symptoms are identical.
Well, identical with the exception of death or increased likelihood of seizures.
I've also been told if I suspect PML it is VERY important to respond quickly so a plasma exchange can be performed.
So, basically, am I supposed to wait for a seizure and I'm on the floor swallowing my tongue to figure out whether I'm having an MS or PML seizure?
So how do I tell?
Any of you guys have any ideas?
Since stopping the Tysabri I've been steadily degrading and gotten MUCH worse to a point I've been embarrassing myself
Update
MSers STOPPING TYSABRI DO IT BECAUSE THEY ARE AT HIGH-RISK OF DEVELOPING PML....
BUT STOPPING TYSABRI LEADS TO REBOUND IN MS DISEASE ACTIVITY
GILENYA APPEARS TO PREVENT THIS REBOUND IF IT'S STARTED WITHIN 4 WEEKS AFTER THE LAST TYSABRI INFUSION
"The study below confirms what we already know; stopping Tysabri/natalizumab leads to rebound in MS disease activity.
Switching to a DMT on a lower-tier of efficacy, i.e. interferon-beta or glatiramer acetate, or taking steroids does not prevent this rebound.
In comparison, a higher-efficacy drug such as
Gilenya/fingolimod appears to prevent this rebound provided it is
started within 4 weeks after the last Tysabri/natalizumab infusion."
"Most MSers stopping Tysabri/natalizumab are doing it because they are at high-risk of developing PML. The major safety concern we have is so called carry-over PML; i.e. PML that presents in the first few months after starting fingolimod.
I am aware of two cases of carry-over PML on fingolimod. Carry-over PML is a problem in that we rely on the immune response to clear you of PML; it takes about 6-8 weeks for fingolimod to wash-out of your system and during this time PML can cause devastating damage. Our practice, to prevent carry-over PML and rebound disease activity, is to do a MRI and lumbar puncture shortly after the last natalizumab infusion. If the spinal fluid analysis shows no JC virus DNA and the MRI shows no evidence of asymptomatic PML we start fingolimod within 4 weeks of the last natalizumab infusion. So far this practice seems to be working; touch wood we have had no cases of carry-over PML."
SHARE THIS BY CLICKING TINY ENVELOPE BELOW
BUT STOPPING TYSABRI LEADS TO REBOUND IN MS DISEASE ACTIVITY
GILENYA APPEARS TO PREVENT THIS REBOUND IF IT'S STARTED WITHIN 4 WEEKS AFTER THE LAST TYSABRI INFUSION
"The study below confirms what we already know; stopping Tysabri/natalizumab leads to rebound in MS disease activity.
Switching to a DMT on a lower-tier of efficacy, i.e. interferon-beta or glatiramer acetate, or taking steroids does not prevent this rebound.
![]() |
| Dr Gavin Giovannoni |
"Most MSers stopping Tysabri/natalizumab are doing it because they are at high-risk of developing PML. The major safety concern we have is so called carry-over PML; i.e. PML that presents in the first few months after starting fingolimod.
I am aware of two cases of carry-over PML on fingolimod. Carry-over PML is a problem in that we rely on the immune response to clear you of PML; it takes about 6-8 weeks for fingolimod to wash-out of your system and during this time PML can cause devastating damage. Our practice, to prevent carry-over PML and rebound disease activity, is to do a MRI and lumbar puncture shortly after the last natalizumab infusion. If the spinal fluid analysis shows no JC virus DNA and the MRI shows no evidence of asymptomatic PML we start fingolimod within 4 weeks of the last natalizumab infusion. So far this practice seems to be working; touch wood we have had no cases of carry-over PML."
SHARE THIS BY CLICKING TINY ENVELOPE BELOW
Subscribe to:
Posts (Atom)












